TGCT Support
  • Home
  • About TGCT
    • Types of TGCT
    • Tumor Location
    • Causes of TGCT
    • Diagnosis >
      • Imaging Features
      • Biopsy
  • Treatment
    • Surgery >
      • Recovery
    • Medication
    • Clinical Trials >
      • Vimseltinib
      • AMB-05X
      • Cabiralizumab
      • Emactuzumab
    • Radiation
  • Get Support
    • Join the Community >
      • Volunteer
      • Support Groups
    • TGCT Specialists
    • Nutrition
    • Pain Management
    • Side Effect Management
    • Glossary of Terms
    • Educational Materials & Videos
    • Webinars
  • News
    • Patient Stories
  • About Us
    • Meet the Team
    • Contact Us
    • Our Store
  • DONATE
  • Home
  • About TGCT
    • Types of TGCT
    • Tumor Location
    • Causes of TGCT
    • Diagnosis >
      • Imaging Features
      • Biopsy
  • Treatment
    • Surgery >
      • Recovery
    • Medication
    • Clinical Trials >
      • Vimseltinib
      • AMB-05X
      • Cabiralizumab
      • Emactuzumab
    • Radiation
  • Get Support
    • Join the Community >
      • Volunteer
      • Support Groups
    • TGCT Specialists
    • Nutrition
    • Pain Management
    • Side Effect Management
    • Glossary of Terms
    • Educational Materials & Videos
    • Webinars
  • News
    • Patient Stories
  • About Us
    • Meet the Team
    • Contact Us
    • Our Store
  • DONATE

Vimseltinib 

Vimseltinib (previously called dcc-3014)

DCC-3014, Vimseltinib (Deciphera) is the name of a medication currently in trial for TGCT.

It is a Phase II/III study, meaning the side effects are being evaluated as well as the effectiveness of the drug. The Phase III trial is known as MOTION.

Preliminary data shows it has an improved tolerability profile and remains effective at shrinking TGCT.

​It is currently recruiting at 18 different global clinical locations. Vimseltinib or a sugar drug (placebo) is given twice weekly for 24 weeks. Following 24 weeks, Vimseltinib is given to all participants.  At any time, patients given the sugar pill can cross over into the Vimseltinib group. The objective of this trial is to review tumor shrinkage at 25 weeks, range of motion, and patient reported pain, stiffness, and function.

​For more information on the trial and the locations, visit the 
Phase II clinical trial website for DCC-3014, Phase III clinical trial website for Vimseltinib or ask your healthcare provider.

To learn more, check out Deciphera's Vimseltinib page. 
​
Picture

TGCT SUPPORT IS A PROGRAM OF THE LIFE RAFT GROUP

Picture
155 US Highway 46, Suite 202                      Wayne, NJ 07470                      support@tgctsupport.org